After a year of margin expansion and record profits, one big Resideo shareholder is testing how much upside is already priced ...
Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback